New hope for stage 4 lung cancer? trial combines experimental drug with standard therapy
Disease control
Not yet recruiting
This study tests whether adding an experimental drug (EIK1001) to standard treatment (pembrolizumab plus chemotherapy) helps people with stage 4 non-small cell lung cancer live longer or stop their cancer from growing. About 750 adults whose cancer has spread will receive either …
Phase: PHASE2, PHASE3 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated May 11, 2026 20:46 UTC